Endava to Acquire GalaxE Solutions to Boost Its Position in North America Healthcare With Delivery from India

Go back to Endava to Acquire GalaxE Solutions to Boost Its Position in North America Healthcare With Delivery from India

Citi Downgrades Endava PLC (ADR) (DAVA) to Neutral, 'Idiosyncratic Factors + Macro Risks'

March 1, 2024 5:30 AM EST

Citi analyst Ashwin Shirvaikar downgraded Endava PLC (ADR) (NYSE: DAVA) from Buy to Neutral with a price target of $40.00 (from $90.00).

The analyst comments "Our below-consensus and below-outlook estimates for Endava proved too high as Endava announced a sharp ~9% cut in revenue expectations. We note that... More